Answers are grounded in this paper and cite their sources.
Several biomarkers have been reported to be associated with survival in breast cancer over the past decades. Unfortunately, it is often difficult to distinguish between the prognostic and predictive values of these proposed markers and independent validations are frequently lacking. Patients with early-stage breast cancer receive various combinations of treatments including surgery, post-operative radiation therapy, adjuvant endocrine treatment and chemotherapy. Each of these can have an impact on survival, and most biomarker studies included heterogeneously treated patient cohorts. The classical methodology of assessing the true prognostic value of a marker was restricted to patients who underwent local regional therapy alone and received no systemic adjuvant treatment.
No takes yet. Share an insight, caveat, or question.
Pusztai et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: